We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · December 31, 2020

Outcomes After Stopping Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia

JAMA Oncology


Additional Info

JAMA Oncology
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
JAMA Oncol 2020 Nov 12;[EPub Ahead of Print], E Atallah, CA Schiffer, JP Radich, KP Weinfurt, MJ Zhang, J Pinilla-Ibarz, V Kota, RA Larson, JO Moore, MJ Mauro, MWN Deininger, JE Thompson, VG Oehler, M Wadleigh, NP Shah, EK Ritchie, RT Silver, J Cortes, L Lin, A Visotcky, A Baim, J Harrell, B Helton, M Horowitz, KE Flynn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading